2020
DOI: 10.3390/medicina56070322
|View full text |Cite
|
Sign up to set email alerts
|

Prognostic Significance of ADAM17 for Gastric Cancer Survival: A Meta-Analysis

Abstract: Background and objectives: The prognostic role of a disintegrin and metalloproteinase (ADAM) 17 has been widely assessed in gastric cancer. However, the results are inconsistent. We performed a meta-analysis to evaluate the prognostic significance of ADAM17 and its association with clinicopathological parameters. Methods: The databases of PubMed, Web of Science, and Embase were searched for relevant articles published up to April 2020. The reported hazard ratios (HRs) and odds ratios (ORs) and their co… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
14
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(14 citation statements)
references
References 45 publications
0
14
0
Order By: Relevance
“…As you will discover in this review, ADAM17 has both beneficial and detrimental effects. Although it has been shown to be beneficial for embryonic development, liver health and adipocyte differentiation, it is also implicated in the pathogenesis of many different diseases including, but not limited to cancer [ 19 ], heart disease [ 20 ], diabetes [ 21 , 22 ], rheumatoid arthritis [ 23 ] and Alzheimer’s disease [ 24 ]. In this review, we aim to highlight the impact of ADAM17 on the progression of Metabolic Syndrome.…”
Section: What Is Adam17?mentioning
confidence: 99%
“…As you will discover in this review, ADAM17 has both beneficial and detrimental effects. Although it has been shown to be beneficial for embryonic development, liver health and adipocyte differentiation, it is also implicated in the pathogenesis of many different diseases including, but not limited to cancer [ 19 ], heart disease [ 20 ], diabetes [ 21 , 22 ], rheumatoid arthritis [ 23 ] and Alzheimer’s disease [ 24 ]. In this review, we aim to highlight the impact of ADAM17 on the progression of Metabolic Syndrome.…”
Section: What Is Adam17?mentioning
confidence: 99%
“…Putative Target Importance Neoplastic Transformation, Proliferation, and Cell Survival ADAM9 and -15 gastric cancer cell lines proliferation [117] ADAM10 Notch1 [67] stem-like phenotype in cancer stem cells and supports anchorage independent growth [67] ADAM12 decreases gastric cancer cell lines proliferation [117] ADAM17 HB-EGF [53] Notch1 [67] reduces apoptosis [135], poor prognosis in gastric cancer [133], induces pro-survival signaling via the EGFR [44,135,136], cancer stem like phenotype, anchorage-independent growth [67] MMP7 (matrilysin-1) promotes proliferation in non-transformed epithelial cells [132] MMP12 (macrophage metalloelastase) inversely correlates with disease outcome [37,134] caspase-3 executioner caspase, activation by caspase-8, -9, or -10 [139], activation induced by H. pylori LPS and induced MMP9 [140], H. pylori induction of anti-apoptotic proteins of the cIAP family to reduce caspase-3-dependent apoptosis [141,142] caspase-8 initiator caspase, limited proteolytic (including autocatalytic) activity, engaged by death receptors, including tumor necrosis factor receptor 1 (TNFR1) and Fas/CD95 [139], TieA-protein-induced apoptosis [143] HtrA HtrA L171 variant was enriched in gastric cancer patients and may increase efficiency in basolateral CagA delivery by H pylori and risk for developing gastric cancer [59] Table 2. Cont.…”
Section: Group/proteasementioning
confidence: 99%
“…MMP7 was shown to promote proliferation in non-transformed epithelial cells [ 132 ]. A meta-analysis revealed ADAM17 as a significant biomarker for poor prognosis in gastric cancer [ 133 ]. In contrast, beneficial effects of MMP12 expression have been discussed and expression levels were suggested to correlate inversely with disease outcome [ 37 , 134 ].…”
Section: The Role Of Proteases In Proliferation Cell Survival and Neo...mentioning
confidence: 99%
“…ADAM17 expression is associated with poor survival (HR = 2.04, 95% CI = 1.66–2.52, p < 0.001), lymph node metastasis (OR = 5.47, 95% CI = 3.98–7.51, p < 0.001) and distant metastasis (OR = 3.50, 95% CI = 1.79–6.87, p < 0.001) in many types of tumors [ 177 ]. In a meta-analysis by Ni et al increased expression of ADAM17 in GC was significantly associated with poor survival, TNM stage and lymph node metastasis [ 178 ]. In a meta-analysis of the expression of ADAM10 and ADAM17 in GC, their increased expression was associated with T3-4 cancer more than T1-2 cancer (OR = 0.29, 95% CI = 0.21–0.40, p < 0.0001), N-positive cancer more than N-negative cancer (OR = 4.36, 95% CI = 2.25–8.45, p < 0.0001), cancer with distant metastasis more than cancer without metastasis (OR = 0.09, 95% CI = 0.02–0.37, p = 0.0008) [ 179 ].…”
Section: Immune Checkpoint Expression In Connection With Clinical Features and The Therapeutic Efficacy Of Their Inhibitionmentioning
confidence: 99%
“…In all analyzed studies with a significant association of ADAM17 expression with survival, ADAM17 expression was associated with a poor prognosis of GC. So, in a meta-analysis by Ni et al ADAM17 expression was associated with poor OS (HR = 2.04, 95% CI = 1.66–2.50), TNM stage (OR = 4.09, 95% CI = 1.85–9.04) and lymph node metastasis (OR = 3.08, 95% CI = 1.13–8.36) [ 178 ]. Significant HR values were obtained by Zhang et al: in their study ADAM17 expression was associated with poor OS (HR = 5.87, 95% CI = 1.59–20.52, p = 0.008), degree of tumor differentiation ( p = 0.006), depth of invasion ( p < 0.0001), lymph node metastasis ( p = 0.02), distant metastasis ( p = 0.02) and TNM stage ( p = 0.03) [ 185 ].…”
Section: Immune Checkpoints As Biomarkers Of Gcmentioning
confidence: 99%